News & Media Press releases & statements Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel OK Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel OK Year All Years 2022 2021 2020 2019 2018 2017 2016 2015 Category All categories Type - Statement - Press release Topic - Corporate and finance - Global health - Partnerships Research area - COVID-19 - Ebola - RSV - Seasonal influenza Uncategorized Keywords Apply filter Advanced Search Search Search Headlines Only Type All Statement Press release Topic All Corporate and finance Global health Partnerships Research area All COVID-19 Ebola RSV Seasonal influenza From To Asset Types Photos Video Audio Documents Events Standard Jul 1, 2022 StatementGlobal healthCOVID-19 Novavax Statement on Prototype Vaccine’s Broad Immune Responses and Accelerated Focus on Omicron BA.4/5 as Recommended by the FDA Download Jun 28, 2022 StatementGlobal healthCOVID-19 Novavax to Participate in Vaccines and Related Biological Products Advisory Committee Review of COVID-19 Vaccines Strain Composition Download Jun 23, 2022 StatementGlobal healthCOVID-19 Novavax Files Supplement to a New Drug Submission in Canada for Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 Download Jun 17, 2022 StatementCOVID-19Seasonal influenza Novavax to Showcase Innovative Vaccine Data at Communicable Diseases & Immunisation Conference 2022 Download Jun 3, 2022 StatementCOVID-19 Novavax Statement on US FDA Briefing Document Related to Myocarditis/Pericarditis Download Jun 2, 2022 StatementGlobal healthCOVID-19 Novavax Files in the United Kingdom for Expanded Conditional Marketing Authorization of COVID-19 Vaccination as a Booster in Adults Aged 18 and Over Download May 31, 2022 StatementGlobal healthCOVID-19 Novavax Initiates Phase 3 Trial of its COVID-19 Omicron Strain Vaccine as a Booster Download May 26, 2022 StatementGlobal healthCOVID-19 FDA Confirms Vaccines and Related Biological Products Advisory Committee Review of Novavax’ COVID-19 Vaccine on June 7, 2022 Download May 25, 2022 StatementGlobal healthCOVID-19 Novavax Announces Participation in Oxford University Com-COV3 Booster Trial of COVID-19 Vaccines in Adolescents Aged 12 Through 15 Download May 20, 2022 StatementGlobal healthCOVID-19 Novavax Files in the European Union for Expanded Conditional Marketing Authorization of COVID-19 Vaccine as a Booster in Individuals Aged 18 and Over Download May 13, 2022 StatementCOVID-19 Novavax Files for Emergency Use Authorization of COVID-19 Vaccine in Taiwan Download May 6, 2022 StatementCOVID-19 Novavax Submits Variations to Expand Australian and New Zealand Provisional Approval of Nuvaxovid™ COVID-19 Vaccine to Adolescents aged 12 Through 17 Years Download May 6, 2022 StatementCOVID-19 Novavax’ COVID-19 Vaccine Nuvaxovid™ Arrives in Singapore Download May 4, 2022 Statement Novavax Requests Expanded Authorization of Nuvaxovid™ COVID-19 Vaccine to Adolescents Aged 12 through 17 Years in Great Britain* Download Dec 15, 2021 StatementCOVID-19 Novavax Statement on PREVENT-19 Phase 3 Clinical Trial Results Publication in the New England Journal of Medicine Download Dec 2, 2021 StatementCOVID-19 Novavax Statement on Omicron Variant Response Download Nov 18, 2021 StatementCOVID-19 Novavax Statement on Publication of Positive Results from First Study of Co-administered COVID-19 and Influenza Vaccines Download Nov 10, 2021 StatementCOVID-19 Novavax Statement on UK and Mexico Phase 3 Clinical Trial Participants Considered Fully Vaccinated in the US Download Oct 20, 2021 StatementCOVID-19 Novavax Reconfirms Confidence in Regulatory Filing Timelines and Manufacturing Quality Download Oct 19, 2021 StatementCOVID-19 Novavax Statement on Initial Com-COV2 Phase 2 Clinical Trial Results Presented at World Vaccine Congress Europe Download Oct 11, 2021 StatementCOVID-19 Complete PREVENT-19 Phase 3 Clinical Trial Results Manuscript for COVID-19 Vaccine Posted to medRxiv Download Sep 17, 2021 StatementCOVID-19 Novavax Statement on Proof of COVID-19 Vaccine Requirements for PREVENT-19 Clinical Trial Participants in the U.S. Download Sep 10, 2021 StatementCOVID-19 Novavax Statement on Takeda Agreement to Provide 150 Million Doses of NVX-CoV2373 to the Government of Japan Download Jun 30, 2021 StatementCOVID-19 Novavax Statement on Proof of Vaccination for Phase 3 Clinical Trial Participants: Updated June 30, 2021 Download Jun 22, 2021 StatementCOVID-19 Novavax Statement on Completion of the National Research Council of Canada Biologics Manufacturing Centre Download Show 5102550100 per page«12»